KAS
CYTK icon

Kestra Advisory Services’s Cytokinetics CYTK Stock Holding History

Kestra Advisory Services’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,115
Closed -$271K – 3285
2026
Q1 		$271K Buy
4,115
+3,664
+812% +$233K ﹤0.01% 2713
2025
Q4 		$28.7K Buy
+451
New +$28.1K ﹤0.01% 4317

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kestra Advisory Services's CYTK Position: Q2 2026 in Review

Kestra Advisory Services sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 4,115 shares — an estimated $271K sold.

Kestra Advisory Services first reported a position in CYTK in Q4 2025 and held it in 2 quarters. The position peaked at $271K in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Kestra Advisory Services reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 4,115 Cytokinetics shares in Q2 2026, an estimated $271K.
  • Kestra Advisory Services first reported a position in Cytokinetics in Q4 2025 and held it in 2 quarters.
  • Kestra Advisory Services's Cytokinetics position peaked at $271K in Q1 2026.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.